Expert Interview
A second look at an investigational RNAi therapeutic in development by Arrowhead Pharmaceuticals, plozasiran (ARO-APOC3), for treatment of severe hypertriglyceridemia and mixed dyslipidemia.
Ticker(s): ARWR- board-certified cardiologist with special interests in lipids management; complex coronary artery disease and peripheral vascular disease interventions; pacemaker implantation; and repair of structural heart defects.
- treats 30-50/year with SHTG
- treats 800-1200 pts with mixed dyslipidemia/year
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
